Vaxxirna is targeting infectious disease areas where the limitations of current vaccine technologies: short-lived protection, cold-chain dependence, injection-only delivery, create the greatest unmet need. Our programs are selected for scientific rationale, global health impact, and the ability to provide meaningful clinical validation of the viRNA™ platform.

Program-specific details, including lead indications and development stages, will be disclosed in accordance with Vaxxirna’s publication and partnering strategy.

Investors and partners seeking pipeline information are invited to request Vaxxirna’s investor deck.